Clinical Trial Update: Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update outlines a Phase 1/2 trial of dose-deescalated 3-fraction stereotactic body radiotherapy for centrally located non-small cell lung cancer, currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Yale University | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING